AllSci News
BioCryst grants Neopharmed Gentili European rights to navenibart for hereditary angioedema, USD 345m deal
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary...
Gyre Therapeutics completes USD 300m acquisition of Cullgen to create integrated US-China biotech company
Gyre Therapeutics (Nasdaq: GYRE) has completed the acquisition of Cullgen Inc., a privately held, clinical-stage biopharmaceutical company focused on...
FDA approves ADMA Biologics’ Asceniv for pediatric immune compromised patients aged two and older
ADMA Biologics announced US FDA approval of a supplemental Biologics License Application for Asceniv (immune globulin intravenous, human – slra 10% liquid),…
Latus Bio closes USD 97m Series A financing for AAV gene therapy pipeline
Philadelphia-based Latus Bio has closed a USD 97 million Series A financing round to advance its AAV gene therapy pipeline, with lead programs targeting...
National Pediatric Cancer Foundation awards USD 1m grant to Children's Hospital Los Angeles for rhabdomyosarcoma research
The National Pediatric Cancer Foundation has awarded a USD 1 million pediatric cancer research grant to JinSeok Park, PhD, at Children's Hospital Los...
Takeda's Tak-881 meets primary endpoint in Phase II/III primary immunodeficiency disease trial
Takeda (TSE:4502/NYSE:TAK) reported that TAK-881, an investigational immune globulin subcutaneous 20% formulation facilitated by recombinant human...
FDA approves Guardant360 CDx companion diagnostic for Arvinas and Pfizer's Veppanu in advanced breast cancer
The US FDA has approved Guardant360 CDx as a companion diagnostic for Veppanu (vepdegestrant), the PROTAC estrogen receptor degrader jointly developed by...
Clene planning NDA filing for CNM-Au8 gold nanocrystal suspension for ALS
Clene Inc. announced plans to file a New Drug Application (NDA) with the US FDA for CNM-Au8, an oral suspension of gold nanocrystals, seeking accelerated...
Bristol-Myers Squibb's CELMoD platform and admilparant advance toward pivotal readouts defining next-decade growth
Bristol-Myers Squibb held its BMY Q1 2026 earnings conference call on April 30, 2026, during which executives signaled that the company's late-stage...
Eli Lilly's Q1'26 Earnings Call: Retatrutide advances as post-incretin pipeline built around cell therapy acquisitions
Eli Lilly's Q1 2026 earnings conference call centered on retatrutide's first positive Phase III data in type 2 diabetes and a sweeping in vivo cell therapy...
FDA approves Incyte’s Jakafi XR for myelofibrosis, polycythemia vera, and graft-versus-host disease
Incyte has received US FDA approval for Jakafi Xr (ruxolitinib) extended-release tablets, a once-daily reformulation of its established JAK1/JAK2 inhibitor, across three…
Archimed acquires Esperion Therapeutics for USD 1.1b, gaining bempedoic acid commercial infrastructure
ARCHIMED has agreed to acquire Ann Arbor, Michigan-based Esperion Therapeutics (Nasdaq: ESPR) in a transaction valued at up to approximately USD 1.1 billion...
Specialised Therapeutics’ Niktimvo wins second global approval in Australia for cGVHD
Singapore-based Specialised Therapeutics has announced that Australia’s Therapeutic Goods Administration (TGA) has approved Niktimvo (axatilimab) for the treatment of chronic graft-versus-host disease…
Ligand moving to terminate TR-Beta Program license with Viking Therapeutics over development breach
Ligand Pharmaceuticals (Nasdaq: LGND) has terminated its TR-Beta Program license with Viking Therapeutics (Nasdaq: VKTX), pulling rights to two small...
Celcuity's gedatolisib triplet beats alpelisib in Phase III breast cancer trial
Celcuity (Nasdaq: CELC) reported that gedatolisib combined with fulvestrant and palbociclib met the primary endpoint of the Phase III VIKTORIA-1 trial,...
The AllSci Brief
Systematic R&D and deal news. Daily.